Using ctDNA to guide treatment for limited metastasis
Part of Cancer clinical trials.
This trial studies if a blood test (ctDNA) can help doctors decide the best treatment for people whose cancer has spread to only a few places. It tests how well local treatments work for this type of limited spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have spread to a limited number of spots (oligometastatic disease)
- You are scheduled to receive local treatment (like radiation or surgery) for these spots
- You are at least 18 years old
- You can provide written and oral consent to participate
- You do not have any other cancer diagnosed in the past 5 years
- You have no medical conditions that would make it unsafe to draw blood
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with solid tumors that have spread to a few spots (5 or fewer) in the body. It tests whether using a focused treatment like radiation or ablation on those spots can help control the cancer long-term.
This trial tests whether using a ctDNA blood test along with standard CT scans can help guide treatment decisions for people with incurable metastatic gastrointestinal cancer. It may help doctors decide sooner whether a treatment is working.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This Phase 2 study tests the best way to choose and then follow treatment when colorectal cancer has spread only to a small number of spots. You may be eligible if your doctors can remove or precisely treat the spots and there’s no sign of additional spread on scans.
This study looks at whether measuring a DNA fragment in the blood (called ctDNA) can help predict how well radiotherapy works for head and neck cancer. It may help doctors better tailor treatment for patients with stage III or IV disease.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
Hear when a new Oligometastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.